You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Amid cuts, Amgen to add jobs in Cambridge

Amgen Inc., the nation’s largest biotechnology company, said Tuesday it will expand its Cambridge research center by an unspecified number of jobs even as it unveiled a restructuring plan that will cut 2,400 to 2,900 jobs and close four sites, in Colorado and Washington state.

The company’s research and development center in Kendall Square currently has about 180 employees. Amgen also runs a satellite site in Woburn, which has 70 workers, and a large manufacturing plant in Warwick, R.I., with 840 workers. All of those operations will remain open.

Continue reading below

“We’ve made a strategic decision to expand our existing presence in Cambridge,” said Cuyler Mayer, a spokesman at Amgen’s headquarters in Thousand Oaks, Calif., near Los Angeles. “We consider that a key biotechnology hub for our business. We believe we will have added access to the knowledge and talent we need to drive our [drug] pipeline forward.”

Mayer said Amgen will not determine how many jobs will be eliminated globally — or how many it will add in Cambridge and South San Francisco, Calif., another site it will expand — until later this year or next year.

The company has multiple drug candidates before the Food and Drug Administration and European regulators.

The shutdowns of Amgen research sites in Seattle and a production site in Bothell, Wash., as well as company operations in Boulder and Longmont, Colo., will take place over the next 18 months, Mayer said.

As part of its restructuring plan, Amgen is expected to offer voluntary retirement packages to employees around the country, including some in Massachusetts.

Several other global biopharmaceutical companies, notably Novartis AG of Switzerland and Sanofi SA of France, have similarly been growing their Boston area research operations even as they have scaled back in other parts of the national and overseas.

Robert Weisman can be reached at robert.weisman@globe.com. Follow him on Twitter @GlobeRobW.
Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.